Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bosutinib for Chronic Myeloid Leukemia

Bosutinib for Chronic Myeloid Leukemia In recent years the availability of several tyrosine kinase inhibitors (TKI) in the therapeutic armamentarium for chronic myeloid leukemia has dramatically changed the objectives and expectations of healthcare providers and patients. For many, but not all, patients the forerunner of TKI, imatinib, is still an excellent treatment option. Unfortunately, nearly 30–40% of imatinib-treated patients discontinue therapy in the long-term, because of failure and/or intolerance. Second-generation tyrosine kinase inhibitors are more potent drugs which are suitable for treatment of approximately 50% of patents for whom imatinib is unsuitable, and with high success and rapid responses. Bosutinib, an orally bioavailable Src/Abl tyrosine kinase inhibitor, has proved to be effective in vitro against resistant chronic myeloid leukemia cells that do not harbor the T315I or V299L ABL kinase domain mutations. During clinical development the manageable safety profile of bosutinib have become evident for both simple and more advanced treatment. In this review we summarize preclinical and clinical data for bosutinib and discuss its ideal field of action in comparison with other TKI. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Bosutinib for Chronic Myeloid Leukemia

Breccia, Massimo; Binotto, Gianni
Oncology and Therapy , Volume 3 (2) – Aug 26, 2015
Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/bosutinib-for-chronic-myeloid-leukemia-xEDULOgb32
Publisher
Springer Journals
Copyright
Copyright © 2015 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2195-6022
DOI
10.1007/s40487-015-0010-y
Publisher site
See Article on Publisher Site

Abstract

In recent years the availability of several tyrosine kinase inhibitors (TKI) in the therapeutic armamentarium for chronic myeloid leukemia has dramatically changed the objectives and expectations of healthcare providers and patients. For many, but not all, patients the forerunner of TKI, imatinib, is still an excellent treatment option. Unfortunately, nearly 30–40% of imatinib-treated patients discontinue therapy in the long-term, because of failure and/or intolerance. Second-generation tyrosine kinase inhibitors are more potent drugs which are suitable for treatment of approximately 50% of patents for whom imatinib is unsuitable, and with high success and rapid responses. Bosutinib, an orally bioavailable Src/Abl tyrosine kinase inhibitor, has proved to be effective in vitro against resistant chronic myeloid leukemia cells that do not harbor the T315I or V299L ABL kinase domain mutations. During clinical development the manageable safety profile of bosutinib have become evident for both simple and more advanced treatment. In this review we summarize preclinical and clinical data for bosutinib and discuss its ideal field of action in comparison with other TKI.

Journal

Oncology and Therapy – Springer Journals

Published: Aug 26, 2015

References

  • Src kinases as therapeutic targets for cancer
    Kim, LC; Song, L; Haura, EB
  • Src signaling in cancer invasion
    Guarino, M
  • Effects of a selective inhibitor of the abl tyrosine kinase on the growth of Bcr-Abl positive cells
    Druker, BJ; Tamura, S; Buchdunger, E
  • The molecular biology of chronic myeloid leukemia
    Deininger, MW; Goldman, JM; Melo, JV
  • Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia
    Druker, BJ; Talpaz, M; Resta, DJ
  • Which tki? An embarrassment of riches for chronic myeloid leukemia patients
    Hughes, T; White, D
  • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    Hochhaus, A; O′Brien, SG; Guilhot, F
  • Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
    Castagnetti, F; Gugliotta, G; Breccia, M
  • Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
    Kantarjian, HM; Giles, FJ; Bhalla, KN
  • Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
    Shah, NP; Guilhot, F; Cortes, JE
  • Nilotinib versus imatinib in patients with newly diagnosed Philadelphia Chromosome-Positive chronic myeloid leukemia in chronic phase: enestnd 3-year follow-up
    Larson, RA; Hochhaus, A; Hughes, TP
  • Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (dasision)
    Kantarjian, HM; Shah, NP; Cortes, JE
  • Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity
    Boschelli, DH; Ye, F; Wang, YD
  • Ski-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice
    Golas, JM; Arndt, K; Etienne, C
  • In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
    Puttini, M; Coluccia, AM; Boschelli, F
  • Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606
    Konig, H; Holyoake, TL; Bhatia, R
  • Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
    Remsing Rix, LL; Rix, U; Colinge, J
  • Population pharmacokinetic and pharmacodynamic analysis of bosutinib
    Hsyu, PH; Mould, DR; Abbas, R
  • A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
    Abbas, R; Hug, BA; Leister, C
  • Bosutinib in the treatment of patients with philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview
    Shen, AQ; Wilson, NM; Gleason, SL
  • Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects
    Abbas, R; Hug, BA; Leister, C
  • Effect of rifampin on the pharmacokinetics of bosutinib, a dual SRC/ABL tyrosine kinase inhibitor, when administered concomitantly to healthy subjects
    Abbas, R; Boni, J; Sonnichsen, D
  • A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects
    Abbas, R; Leister, C; Sonnichsen, D
  • Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia
    Hsyu, PH; Mould, DR; Upton, RN
  • Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects
    Abbas, R; Chalon, S; Leister, C
  • Safety and efficacy of bosutinib (SKI-606) in chronic phase philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
    Cortes, JE; Kantarjian, HM; Brummendorf, TH
  • Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up
    Gambacorti-Passerini, C; Brummendorf, TH; Kim, DW
  • Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial
    Cortes, JE; Kim, DW; Kantarjian, HM
  • Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
    Brummendorf, TH; Cortes, JE; Souza, CA
  • Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
    Gambacorti-Passerini, C; Cortes, JE; Lipton, JH